



Genomic analysis of the endosomal sorting required for transport complex III pathway genes as therapeutic and prognostic biomarkers for endometrial carcinoma

Ye Yang^{1^}, Min Wang²

¹Obstetrics and Gynecology Department, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; ²General Surgery Department, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Contributions: (I) Conception and design: Y Yang; (II) Administrative support: Y Yang; (III) Provision of study materials or patients: Y Yang; (IV) Collection and assembly of data: Both authors; (V) Data analysis and interpretation: Both authors; (VI) Manuscript writing: Both authors; (VII) Final approval of manuscript: Both authors.

Correspondence to: Min Wang. Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 85 Wujin Road, Hongkou, Shanghai 200080, China. Email: wangmin0501@hotmail.com.

Background: The genes involved in the endosomal sorting required for transport complex (ESCRT)-III pathway is a protective mechanism that delays cell death by repairing damaged plasma membranes. We aimed to evaluate if targeting *ESCRT-III* genes may be used as biomarkers for predicting the clinical outcomes of endometrial carcinoma (EC).

Methods: Transcriptome RNA sequence (RNA-seq) data and genomic information of EC samples were obtained from The Cancer Genome Atlas (TCGA). The expression level, pathological relationship, pathway alterations, mutation, functional enrichment, associations with tumor infiltrating lymphocytes (TILs), and survival information of *ESCRT-III* genes including charged multivesicular body protein 2A (*CHMP2A*), *CHMP2B*, *CHMP3*, *CHMP4B*, *CHMP4C*, *CHMP5*, *CHMP5*, and *CHMP7* in EC and normal tissues were explored through multiple datasets analysis.

Results: Our study demonstrated that *CHMP2B*, *CHMP3*, *CHMP4B*, *CHMP5*, *CHMP5*, and *CHMP7* were significantly lower, whereas *CHMP2A* and *CHMP4C* were significantly higher in EC tissue than in normal tissue. All ESCRT pathway genes were significantly differentially expressed between tumor grades 2 and 3 and were positively correlated with each other. Except for *CHMP5*, the other seven ESCRT pathway genes were the most frequently mutated genes in the EC samples among all cancer types. Moreover, *CHMP2A* and *CHMP7* had better prognostic potential in EC. *CHMP2A*, *CHMP4B*, and *CHMP7* were significantly correlated with all four molecular subtypes in TCGA. Increased expression of *CHMP2A* and *CHMP7* and decreased expression of *CHMP4B* were observed in EC samples than in serous carcinoma type samples. Furthermore, they were associated with tumor stages 1 and 2 and good survival outcomes for EC. Functional analysis revealed that the *ESCRT-III* genes were involved in the biological process (BP) of the membrane budding and multivesicular body (MVB) pathway; *CHMP2A* and *CHMP7* participated in the ESCRT and ESCRT III complex disassembly, while *CHMP5* was involved in ESCRT and ESCRT III complex assembly.

Conclusions: Mutations in *CHMP2A* and *CHMP7* correspond to a better prognostic potential in EC. Upregulation of *CHMP2A* and *CHMP7* and downregulation of *CHMP4B* are good prognostic indicators of the histological type, early tumor grade, and promising survival markers, thus becoming potential biomarkers and therapeutic targets for EC.

Keywords: *ESCRT-III*; *CHMP2A*; *CHMP4B*; *CHMP7*; endometrial carcinoma (EC)

[^] ORCID: 0000-0002-4180-2822.

Submitted Mar 11, 2022. Accepted for publication Jul 08, 2022.

doi: 10.21037/tcr-22-660

View this article at: <https://dx.doi.org/10.21037/tcr-22-660>

Introduction

Endometrial carcinoma (EC) is one of the most common gynecological cancers worldwide, with an estimated new cases and deaths of 65,950 and 12,550, respectively (1). EC has two subgroups, namely, types I and II. Type I is characterized by an upregulation of hormonal receptors. It consists of 60–70% of EC and histological grades 1 and 2. Type II is characterized by low levels of estrogen and progesterone receptor expression. Moreover, it is associated with high-grade EC and serous or clear cell carcinoma with poor prognosis (2). After surgical resection, chemotherapy and radiotherapy for EC, the 5-year disease-free survival (DFS) of patients diagnosed in the early stages, stages III or IV, and recurrent or metastatic disease decreased progressively to 74.2–90.8%, 57.3–66.2%, 20.1–25.5%, and 16%, respectively (3). Targeted therapies for tyrosine kinases and immunotherapy using immune-checkpoint inhibitors (4) are clinical strategies used in cancer treatment. These modalities aim to kill tumor cells and protect normal cells.

The endosomal sorting required for transport complex III (*ESCRT-III*) acts as a protective mechanism that delays cell death by repairing damaged plasma membranes due to necroptosis (5), pyroptosis (6), and ferroptosis (7). The *ESCRT-III* complex incorporates charged multivesicular body protein 2A (*CHMP2A*), *CHMP2B*, *CHMP3*, *CHMP4B*, *CHMP4C*, *CHMP5*, *CHMP5*, and *CHMP7*, which belong to the chromatin-modifying protein/charged multivesicular body protein (CHMP) family (8) (Figure S1). These are involved in the MVB sorting pathway and are important in recycling and degradation of membrane proteins. *ESCRT-I*, *ESCRT-II*, and *ESCRT-III*, as well as VPS4A and ALIX were triggered by Ca²⁺ influx, recruited to damaged lysosomes and mediated lysosomal membrane repair (8). Detailed information on the location and synonyms of these eight *ESCRT-III* genes is listed in Tables S1,S2. Since regulated cell death usually occurs in drug resistant tissues during EC therapy (9), we aimed to determine whether *ESCRT-III* genes might function as potential targets in the treatment and prognosis of EC.

Searching for tumor genomic biomarker using

microarray RNA sequencing (RNA-Seq) data was recently applied to determine cancer prognosis. In this study, we performed bioinformatics technology with a high-throughput screening data to identify the *ESCRT-III* pathway gene signature in EC using the UALCAN, Clinical Proteomic Tumor Analysis Consortium (CPTAC) Confirmatory/Discovery, TISIDB, Gene Expression Profiling Interactive Analysis (GEPIA), and NIH National Cancer Institute CDC Data Portal dataset on the uterine corpus endometrial carcinoma (UCEC) dataset of the Cancer Genome Atlas (TCGA) database. Data on gene expression profiles, pathological relationship, somatic mutation status, function enrichment pathway, correlation with tumor infiltrating lymphocytes (TILs), and survival analysis were generated to assess if *ESCRT-III* pathway genes could be regarded as potential therapeutic targets and candidate prognostic biomarkers for EC. We present the following article in accordance with the STREGA reporting checklist (available at <https://tcr.amegroups.com/article/view/10.21037/tcr-22-660/rc>).

Methods

Acquisition of data on *ESCRT-III* pathway genes

This study conformed to the provisions of the Declaration of Helsinki (as revised in 2013). Data on the transcriptional levels of over- and under-expressed *ESCRT* pathway genes as determined by Transcriptome RNA sequence (RNA-Seq) analysis were collected using the UALCAN analysis (<http://ualcan.path.uab.edu>) (EC: 546; normal: 35) (10) from the UCEC dataset of the TCGA database (<https://portal.gdc.cancer.gov/>). We also conducted GEPIA (<http://gepia.cancer-pku.cn/>) (11) for data mining and visualization of the RNA sequencing expression data to validate the expression profiles of the *ESCRT* pathway genes in UCEC primary tumors (n=174) from TCGA-UCEC and GTEx-Uterus projects (12). The matched TCGA normal and GTEx data were combined into the normal group (n=91). The default parameters were |Log₂FC| Cutoff of 1, P value cutoff of 0.01, and log₂ (transcripts per million, TPM +1) for log-

scale were used. A jitter size of 0.4 was generated. Z-values representing standard deviations from the median across EC and normal endometrial tissue samples were identified using the Clinical Proteomic Tumor Analysis Consortium (CPTAC) Confirmatory/Discovery dataset (<http://ualcan.path.uab.edu/analysis-prot.html>) (13) (EC: 100; normal: 31) and normalized by Log₂ spectral count ratio values both in each sample profile and across samples.

Clinical pathological relationship and pathway analyses of the ESCRT genes

The relationship between ESCRT genes and basic clinical pathological information, including subtype, tumor grade, histology, individual cancer stages, and methylation status, were further explored using the UALCAN and CPTAC datasets. We systematically assessed the ESCRT genes involved in key pathways across EC samples based on the CPTAC dataset, which were represented by Z-values. Associations of the *ESCRT-III* pathway gene expression and immune/molecular subtypes across EC analyzed using the Kruskal-Wallis Test $-\log_{10}(P \text{ value})$ were identified on the TISIDB (<http://cis.hku.hk/TISIDB/index.php>) (14) dataset.

Function enrichment and pathway analyses of the ESCRT pathway genes

To obtain the enriched biological functions and pathways of the ESCRT pathway genes, we conducted the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses on TISIDB. Statistical significance was set at $P < 0.05$. Connections among the ESCRT pathway gene expression were analyzed via the Pearson's correlation on the GEPIA dataset.

Validation of ESCRT gene mutations in the EC samples

We obtained the mutation data on the ESCRT pathway genes in the TCGA-UCEC cohort from the NIH National Cancer Institute GDC Data Portal database (<https://portal.gdc.cancer.gov>). We calculated the number of cases of ESCRT genes affected by simple somatic mutation (SSM) across the TCGA project (n=530). Cases affected by copy number variation (CNV) gains and losses in the TCGA database (n=510) were also analyzed computationally. Disease type in the UCEC project included adenomas, adenocarcinomas, cystic, mucinous, serous, and epithelial neoplasms. Statistical calculations of mutation types,

including somatic mutations, CNV losses, CNV gains, SSM affected, variant effect predictor (VEP) impact mutation, Sorting Intolerant From Tolerant (SIFT) impact mutation, Polyphen Impact Mutation, Consequence Type Mutation, Type Mutation and Variant Caller Mutation were obtained and listed in [Table S3](#). The frequency and pathogenicity of the variants in the exons were determined using bioinformatic prediction tools. We also gathered the clinical survival time and status of the EC patients.

Association between gene expression and TILs

We utilized the online tools, TISIDB and GEPIA2021 (<http://gepia2021.cancer-pku.cn/sub-expression.html>), based on the TCGA database using Spearman correlations to investigate the correlations between genes and their immune microenvironment (15). The relative abundance of 28 TIL types was determined using gene set variation analysis (GSVA) based on gene expression profiles (16).

Survival analysis

To screen the relationship between the expression profiles of the ESCRT pathway genes and the overall survival (OS) between high- and low-expression groups from the TCGA-UCEC dataset, we inferred the Kaplan-Meier survival curves on UALCAN [N (high *vs.* low/medium) = 137 *vs.* 408] and TISIDB analysis. Genes with a statistical significance, as determined by conducting the log-rank test ($P < 0.05$), were considered prognostic genes of EC. We also carried out a univariate Cox proportional hazards regression analysis in GEPIA with EC samples that had high and low expression levels in 86 cases from the TCGA to evaluate their OS and DFS. The Cox proportional hazard ratio (HR) was based on the Cox PH model, while the 95% confidence interval (CI) was included in the survival plot as a dotted line. The median expression threshold for splitting the high- and low-expression cohorts as group cutoff was established. Patients who exhibited an upregulation showed expression values > third quartile. They were then divided into high- or low-expression groups with a median group cutoff of 50%. ESCRT gene mutations associated with survival rates were collected.

Statistical analysis

RNA-seq expression of the TPM of ESCRT pathway genes in the TCGA-UCEC and GTEx-Uterus data,

clinicopathological relationships, and pathways were analyzed via ANOVA. The ESCRT pathway genes associated with immune and molecular subtypes were analyzed using the Kruskal-Wallis test $-\log_{10}(P \text{ value})$. The Chi-square and the Fisher's exact tests were used to compare the mutations. The Spearman's correlation test was used to explore the correlation between gene expression levels and the immune cell types. The Kaplan-Meier survival curves were used to analyze the OS, and univariate Cox proportional hazards regression analysis was used to evaluate the OS and DFS. The statistical significance was set at $P < 0.05$.

Online database

The online databases were as follows: TCGA (<https://portal.gdc.cancer.gov/>); UALCAN (<http://ualcan.path.uab.edu>) (10); TISIDB (<http://cis.hku.hk/TISIDB/index.php>) (14); GEPIA: Gene Expression Profiling Interactive Analysis (<http://gepia.cancer-pku.cn/>) (11); GEPIA2021 (<http://gepia2021.cancer-pku.cn/sub-expression.html>); CPTAC Confirmatory/Discovery dataset (<http://ualcan.path.uab.edu/analysis-prot.html>) (13); and NIH National cancer institute CDC Data Portal database (<https://portal.gdc.cancer.gov>).

Results

Validation of the ESCRT-III pathway genes in EC samples

We investigated the transcriptional RNA expression levels of the key genes in the ESCRT-III pathway in EC and normal endometrial tissues. *CHMP2B*, *CHMP5*, *CHMP5*, and *CHMP7* were significantly lower, while *CHMP2A* and *CHMP4C* were significantly higher in EC samples ($n=546$) than in normal endometrial samples ($n=35$) in the UALCAN analysis of the TCGA-UCEC database (Figure S2A, Table S4). We also verified the expression values of the ESCRT genes by conducting the GEPIA analysis, which indicated a significantly higher expression level of *CHMP4C* in the EC samples ($n=174$) than in the normal samples ($n=91$) on the TCGA-UCEC and GTEx-Uterus data ($n=13$). Genes, such as *CHMP2A*, *CHMP4B*, and *CHMP5*, have higher levels of expression (Figure S2B, Table S4). On the other hand, *CHMP2B*, *CHMP3*, *CHMP5* and *CHMP7* had lower levels of expression in the EC samples. In addition, differential analysis through CPTAC characterized by Z-values revealed that *CHMP2A*, *CHMP2B*, *CHMP3*, and

CHMP4B were markedly lower in the EC samples ($n=100$) and normal endometrial tissues ($n=31$), whereas *CHMP4C* and *CHMP5* showed significantly higher differences in EC samples (Figure S2C, Table S4). *CHMP2A* had a higher level of expression on the UALCAN dataset than on the CPTAC. *CHMP5* had a significantly lower expression on the UALCAN dataset than on the CPTAC. This may possibly be due to different sample sizes and comparison methods with transcriptional RNA expression levels on UALCAN, GEPIA, and the Z-value of standard deviations on CPTAC.

Analysis of the clinical pathological characteristics of the ESCRT-III pathway genes in EC samples

We further compared the expression profiles of ESCRT pathway genes in different tumor stages, grades, subtypes, histological/immune/molecular subtypes, TP53 mutants, methylation, and pathways altered on the TCGA-UCEC and GTEx-Uterus datasets in the UALCAN, CPTAC, and TISIDB analyses, respectively. In the UALCAN analysis, *CHMP2A*, *CHMP2B*, *CHMP4C*, *CHMP5*, and *CHMP7* were significantly differentially expressed among the International Federation of Gynecology and Obstetrics (FIGO) stages 1 to 3 and the normal sample. Different analyses revealed a significantly increased expression of *CHMP2A*, *CHMP4C*, and *CHMP7*, as well as decreased expression of *CHMP2B* and *CHMP5* in endometrioid and serous carcinoma samples compared with normal samples. In addition, *CHMP2A*, *CHMP4B*, *CHMP5*, and *CHMP7* were significantly different between the endometrioid and serous carcinoma samples. An increase in the expression of *CHMP2A* and *CHMP7* and a decrease in the expression of *CHMP4B* were observed in the EC samples compared with the serous carcinoma samples. *CHMP2A*, *CHMP4B*, *CHMP4C*, *CHMP5*, and *CHMP7* were significantly associated with TP53 mutation status in EC samples. Moreover, we found that the methylation status of *CHMP2A*, *CHMP2B*, *CHMP4C*, and *CHMP5* was strongly correlated with their expression levels (Figure 1A, Table S4). In summary, we found that *CHMP2B*, *CHMP3*, *CHMP4B*, *CHMP5*, and *CHMP7* were significantly downregulated, while *CHMP2A*, *CHMP4C* were significantly upregulated in the EC samples.

In the CPTAC analysis, all ESCRT pathway genes were significantly differentially expressed between histologic grades 2 and 3. *CHMP2A*, *CHMP2B*, *CHMP3*, *CHMP4B*, and *CHMP4C* were significantly differentially expressed between grade 1, grade 2, and normal samples. To




Figure 1 Correlation analysis of the ESCRT pathway genes in clinical pathological characteristics of type, FIGO stage, histological grade, histological subtypes, TP53 mutant, and methylation, which are visualized using the cluster heat maps in (A) UALCAN and (B) CPTAC dataset, and (C) pathway altered. ESCRT, Endosomal Sorting Complex Required for Transport; FIGO, International Federation of Gynecology and Obstetrics; CPTAC, Clinical Proteomic Tumor Analysis Consortium; N, normal; O, others; G, grade, defined as G1, well-differentiated; G2, moderately differentiated; G3, poorly differentiated or undifferentiated; S, stage; EC, endometrioid carcinoma; SC, serous carcinoma; MCA, mixed-cell adenocarcinoma; TP53-M, TP53 mutant; TP53-NM, TP53 non-mutant.

investigate the correlations between the pathway alterations, *CHMP2A*, *CHMP2B*, *CHMP3*, *CHMP4B*, *CHMP4C*, and *CHMP5* were differentially expressed between endometrial cancer tissues (n=100) and normal endometrial tissues (n=31) in HIPPO, WNT, mTOR, NRF2, RTK, P53/Rb, SWI-SNF, MYC/MYCN pathway, and chromatin modifier status. This was determined by conducting the Pearson correlation analysis (Figure 1B, Table S4).

TISDIB analysis showed that *CHMP2A*, *CHMP4B*, and *CHMP5* were significantly associated with tumor stage, while *CHMP2A*, *CHMP2B*, *CHMP4B*, *CHMP4C*, *CHMP5*, and *CHMP7* were significantly differentially expressed among different tumor grades. Except for *CHMP7*, all other ESCRT genes were significantly associated with immune subtypes, including wound healing, IFN-gamma dominant, inflammatory, lymphocyte depleted, immunologically quiet, and TGF- β dominant. This was determined by performing the Kruskal-Wallis test (Figure S3). *CHMP2A*, *CHMP4B*, *CHMP5*, and *CHMP7* were significantly associated with a molecular subtype, including POLE (DNA polymerase epsilon), low copy number (CN-LOW), high copy number (CN-HIGH), and microsatellite instability (MSI) (Table S4).

Functional enrichment analysis

GO and KEGG enrichment analyses were performed to determine the biological significance of the genes involved in the ESCRT pathway. Endocytosis (I04144) was the most significantly enriched KEGG pathway analysis, which showed that ESCRT genes were significantly enriched in the endosomal sorting complex required for transport (ESCRT) (hsa917729), membrane trafficking (R-HAS-199991), vesicle-mediated transport (R-HAS-5653656), and macroautophagy (R-HAS-1632852). The main cellular components (CC) were the ESCRT complex (GO:0036452), ESCRT III complex (GO:0000815), endosome membrane (GO:0010008), late endosome (GO:0005770), late endosome membrane (GO:0031902), and endosomal part (GO:0044440).

The GO analysis demonstrated that all the ESCRT pathway genes (*CHMP2A*, *CHMP2B*, *CHMP3*, *CHMP4B*, *CHMP4C*, *CHMP5*, *CHMP5*, and *CHMP7*) were mainly involved in the biological process (BP) of membrane budding (GO:0006900), endosome organization (GO:0007032), endosomal transport (GO:0016197), multivesicular body organization (GO:0036257),

Table 1 ESCRT pathway genes mutation across TCGA project on NIH national cancer institute CDC Data Portal database

	Symbol							
	CHMP2A	CHMP2B	CHMP3	CHMP4B	CHMP4C	CHMP5	CHMP6	CHMP7
Project								
SSM (N=530)								
SSM affected cases	21	26	15	22	14	19	9	36
SSM affected cases in TCGA %	0.0396	0.0491	0.0283	0.0415	0.0264	0.0358	0.017	0.0679
CNV (N=510)								
CNV gains	26	11	8	22	14	21	53	3
CNV gains in TCGA %	0.0510	0.0216	0.0157	0.0431	0.0275	0.0412	0.1039	0.0059
CNV losses	23	23	9	11	5	5	7	32
CNV losses in TCGA %	0.0451	0.0451	0.0176	0.0216	0.0098	0.0098	0.0137	0.0627
All SSM affected cases in UCEC	70	59	32	55	31	45	28	68
Somatic mutation	22	35	16	24	19	22	9	43
Somatic mutation in all SSM affected cases in UCEC %	0.3143	0.5932	0.5	0.4364	0.6129	0.4888	0.3214	0.6324
Disease type								
Adenomas and adenocarcinomas	32	31	18	32	21	26	28	40
Cystic, mucinous and serous neoplasms	38	28	13	23	10	19	0	28
Epithelial neoplasms			1					
Survival								
Dead	13	10	5	10	8	14	16	9
Alive	57	49	27	45	23	31	51	59
Survival rate	0.82	0.72	0.81	0.76	0.68	0.65	0.25	0.84
Interval of last follow-up (Year)	5.095	5.142	5.136	5.106	5.106	5.095	5.008	5.106

ESCRT, endosomal sorting complex required for transport; TCGA, The Cancer Genome Atlas; CNV, copy-number variant; SSM, simple somatic mutation; SNV, single nucleotide variation; UCEC, uterine corpus endometrial carcinoma.

multivesicular body assembly (GO:0036258), multi-organism membrane organization (GO:0044803), and multi-organism membrane budding (GO:1902592), which were related to the main ESCRT function. In addition, *CHMP5* participated in the ESCRT complex assembly (GO:1904895), ESCRT III complex assembly (GO:1904902), *CHMP2A*, *CHMP5*, and *CHMP7*, which participated in the ESCRT complex disassembly (GO:1904896) and ESCRT III complex disassembly (GO:1904903). In addition, *CHMP3* was involved in the regulation of early endosome to late endosome transport

(GO:2000641). On the other hand, *CHMP2B*, *CHMP3*, and *CHMP5* were involved in the endosome-to-lysosome transport (GO:0008333). *CHMP3* and *CHMP5* were involved in the multivesicular body sorting pathway (GO:0071985). *CHMP4B* was involved in the protein localization to the membrane (GO:0072657), membrane fission (GO:0090148), and the establishment of protein localization to the membrane (GO:0090150) (Figure 1C). Detailed information on the above mentioned involvements is shown in Table 1.

The Pearson correlation coefficient analysis results demonstrated that all of the concerned genes enriched

in the ESCRIhsa917729) KEGG pathway in the GEPIA dataset were connected with each other significantly by transcripts per million (TPM) expression values (Figure S4).

ESCRT gene mutations in the EC samples

We observed seven ESCRT pathway genes that were most frequently mutated in the EC samples obtained from the simple somatic mutation (SSM) TCGA cohort (n=530), which included various cancer types, including *CHMP2A* (3.96%), *CHMP2B* (4.91%), *CHMP3* (2.83%), *CHMP4B* (4.15%), *CHMP4C* (2.64%), *CHMP5* (3.58%), and *CHMP7* (6.97%). *CHMP5* (1.70%) was ranked third on the GDC Data Portal (Figure S5). Different mutation categories of the ESCRT genes in the TCGA-UCEC project showed that moderate somatic mutations and missense mutations were the most common types (Figure 2A), *CHMP7* ranked most of the various mutations type. Also, *CHMP5* firstly showed CNV gains (Figure 2B). Moreover, the ESCRT pathway genes frequently mutated in the modifier of VEP impact mutation (Figure 2C), deleterious and tolerated of SIFT impact mutation (Figure 2D), probably_damaging and benign of polyphen impact mutation (Figure 2E), missense_variant, downstream_gene_variant, 3_prime_UTR_variant of consequence type mutation (Figure 2F), single base substitution of type mutation (Figure 2G) and somaticsniper mutation (Figure 2H) (Table 2, Table S3).

ESCRT genes associated with TILs

We explored the correlation between the expression of ESCRT genes and TILs, including 28 distinct immune cell types in the EC samples (n=546) in the TCGA-UCEC database with Spearman correlations using the online tools, TISIDB and GEPIA2021. We found that *CHMP2A*, *CHMP3*, *CHMP4B*, *CHMP5*, *CHMP5*, and *CHMP7* were positively correlated with the infiltration of CD8. *CHMP2B*, *CHMP3*, *CHMP4B*, *CHMP4C*, *CHMP5*, and *CHMP7* were positively correlated with the infiltration of CD4. *CHMP4B*, and *CHMP5* were positively correlated with the infiltration of Tregs. *CHMP3*, *CHMP4B*, and *CHMP5* were positively correlated with the infiltration of NK cells. On the other hand, *CHMP2A* and *CHMP5* were negatively correlated with the infiltration of CD4. *CHMP4C* was negatively correlated with the infiltration of NK and Treg. *CHMP2B* and *CHMP4C* were negatively correlated with the infiltration of CD8, B cells, and macrophages.

CHMP2A, *CHMP3*, *CHMP5*, and *CHMP7* were negatively correlated with B cells (Figure 3A,3B, Table S5). We also detected *CHMP2A* (P=0.0081), *CHMP4B* (P=0.0005), *CHMP4C* (P=0.0002), *CHMP5* (P=0.0231) and *CHMP5* (P=0.0061) were significantly related with TILs (rho value) by multiple liner regression (Table 3). Significant differences between the ESCRT genes and TILs were observed in the TCGA-UCEC tumor, normal, and GTEx-uterus datasets in the GEPIA analysis, in which the parameters were grouped by tissue (P<0.05) (Figure 3C, Table S5). These results indicate that the *ESCRT-III* pathway genes may be effective markers in EC immunotherapy.

Survival analysis and efficacy evaluation of the ESCRT genes

We performed the Kaplan-Meier survival analysis in UALCAN (Figure S6A). The patients were assigned to high (n=136) or low/medium (n=407) expression groups. The univariate Cox regression analysis in TISIDB (Figure S6B) from the TCGA-UCEC database was used to predict the prognostic values of the ESCRT genes on the OS of patients with EC. The Univariate Cox proportional hazards regression analysis in the GEPIA from TCGA also evaluated OS and DFS in patients with EC. We found that a low expression of *CHMP4B* (log-rank P=0.037) in UALCAN and a high expression of *CHMP2A* in TISIDB (log-rank P=0.0203) had a favorable OS for EC, while high expression of *CHMP2A* [(log-rank) P=0.016, hazard ratio (HR) (high) =0.44, P(HR) =]0.018) and *CHMP7* [(log-rank) P=0.027, HR (high) =0.47, P(HR) =0.03] in GEPIA were positively correlated with a better prognosis of EC (Figure S6C).

In addition, we also performed a survival analysis using the Kaplan-Meier method on the ESCRT mutation genes; the 5-year OS rates/intervals of the last follow-up were as follows: *CHMP2A* (82%, 5.095), *CHMP2B* (72%, 5.142), *CHMP3* (81%, 5.136), *CHMP4B* (76%, 5.106), *CHMP4C* (68%, 5.106), *CHMP5* (65%, 5.095), *CHMP5* (25%, 5.008), and *CHMP7* (84%, 5.106) (Figure S7). The *CHMP5* mutations positively correlated with a spoor prognosis. *CHMP2A*, *CHMP3*, and *CHMP7* mutations demonstrated a good potential for being a prognostic tool in patients with EC (Figure S6, Table S6).

Discussion

Type I EC is associated with microsatellite instability




Figure 2 The ESCRT pathway gene mutation types in EC based on the different categories on the TCGA-UCEC database. The tumor mutation burden of each sample is displayed using various colors in the box plots. (A) Somatic mutation; (B) SSM and CNV; (C) VEP impact mutation; (D) SIFT impact mutation; (E) Polyphen impact mutation; (F) consequence type mutation; (G) type mutation; (H) Variant caller mutation. ESCRT, Endosomal Sorting Complex Required for Transport; EC, endometrial carcinoma; TCGA-UCEC, The Cancer Genome Atlas uterine corpus endometrial carcinoma; SSM, simple somatic mutation; CNV, copy-number variant; SNV, single nucleotide variant; VEP, variant effect predictor; SIFT, Sorting Intolerant From Tolerant.

hypermutated (MSI-H) and a copy-number low (CNL) integrated genomic categories in TCGA and frequent mutations in the mTOR pathway (2). Type II EC is

characterized by a copy-number high (CN-H) and frequent mutation of TP53 (17). We found that *CHMP2B*, *CHMP3*, *CHMP4B*, *CHMP5*, *CHMP5*, and *CHMP7* were

Table 2 The whole results of GO and KEGG enrichment analysis of the ESCRT genes in EC

Ontology ID	Description	Genes
BP		
GO:0000045	Autophagosome assembly	<i>CHMP4B</i>
GO:0000070	Mitotic sister chromatid segregation	<i>CHMP2A, CHMP2B, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7</i>
GO:0000226	Microtubule cytoskeleton organization	<i>CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5</i>
GO:0000281	Mitotic cytokinesis	<i>CHMP4B,</i>
GO:0000819	Sister chromatid segregation	<i>CHMP2A, CHMP2B, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7</i>
GO:0000910	Cytokinesis	<i>CHMP4B, CHMP4C,</i>
GO:0000920	Cell separation after cytokinesis	<i>CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7</i>
GO:0001881	Receptor recycling	<i>CHMP5</i>
GO:0001894	Tissue homeostasis	<i>CHMP4B</i>
GO:0001919	Regulation of receptor recycling	<i>CHMP5</i>
GO:0006612	Protein targeting to membrane	<i>CHMP4B</i>
GO:0006620	Posttranslational protein targeting to membrane	<i>CHMP4B</i>
GO:0006887	Exocytosis	<i>CHMP2A,</i>
GO:0006900	Membrane budding	<i>CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7</i>
GO:0006914	Autophagy	<i>CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP6</i>
GO:0006997	Nucleus organization	<i>CHMP2A, CHMP2B, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7</i>
GO:0006998	Nuclear envelope organization	<i>CHMP2A, CHMP4B, CHMP7</i>
GO:0007032	Endosome organization	<i>CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7</i>
GO:0007033	Vacuole organization	<i>CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7</i>
GO:0007034	Vacuolar transport	<i>CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7</i>
GO:0007040	Lysosome organization	<i>CHMP5</i>
GO:0007041	Lysosomal transport	<i>CHMP2B, CHMP5</i>
GO:0007051	Spindle organization	<i>CHMP2A, CHMP2B, CHMP4B, CHMP4C, CHMP5</i>
GO:0007059	Chromosome segregation	<i>CHMP2A, CHMP2B, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7</i>
GO:0007067	Mitotic nuclear division	<i>CHMP2A, CHMP2B, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7</i>
GO:0007080	Mitotic metaphase plate congression	<i>CHMP2A, CHMP2B, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7</i>
GO:0007088	Regulation of mitotic nuclear division	<i>CHMP2A, CHMP2B, CHMP4B, CHMP4C, CHMP5</i>

Table 2 (continued)

Table 2 (continued)

Ontology ID	Description	Genes
GO:0007098	Centrosome cycle	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5
GO:0007099	Centriole replication	CHMP2A
GO:0007346	Regulation of mitotic cell cycle	CHMP2A, CHMP2B, CHMP4B, CHMP4C, CHMP5
GO:0008333	Endosome to lysosome transport	CHMP2B, CHMP3, CHMP5
GO:0009838	Abscission	CHMP4C
GO:0010324	Membrane invagination	CHMP2A
GO:0010458	Exit from mitosis	CHMP2A, CHMP4B, CHMP7
GO:0010506	Regulation of autophagy	CHMP4B
GO:0010507	Negative regulation of autophagy	CHMP4B
GO:0010639	Negative regulation of organelle organization	CHMP2A, CHMP4B
GO:0010824	Regulation of centrosome duplication	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5
GO:0010826	Negative regulation of centrosome duplication	CHMP2A
GO:0010948	Negative regulation of cell cycle process	CHMP2A, CHMP4C
GO:0016050	Vesicle organization	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7
GO:0016197	Endosomal transport	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7
GO:0016236	Macroautophagy	CHMP3, CHMP4B
GO:0016241	Regulation of macroautophagy	CHMP4B
GO:0016242	Negative regulation of macroautophagy	CHMP4B
GO:0016482	Cytosolic transport	CHMP3
GO:0017157	Regulation of exocytosis	CHMP2A
GO:0019058	Viral life cycle	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7
GO:0019068	Virion assembly	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7
GO:0019076	Viral release from host cell	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C
GO:0031023	Microtubule organizing center organization	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5
GO:0031468	Nuclear envelope reassembly	CHMP4B, CHMP7
GO:0032465	Regulation of cytokinesis	CHMP4C
GO:0032466	Negative regulation of cytokinesis	CHMP4C
GO:0032886	Regulation of microtubule-based process	CHMP4B, CHMP5
GO:0032386	Regulation of intracellular transport	CHMP3
GO:0032509	Endosome transport via multivesicular body sorting pathway	CHMP2B, CHMP3
GO:0032510	Endosome to lysosome transport via multivesicular body sorting pathway	CHMP2B, CHMP3

Table 2 (continued)

Table 2 (continued)

Ontology ID	Description	Genes
GO:0032886	Regulation of microtubule-based process	CHMP2A, CHMP2B, CHMP3, CHMP4B
GO:0032984	Macromolecular complex disassembly	CHMP2A, CHMP2B, CHMP5, CHMP7
GO:0036257	Multivesicular body organization	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7
GO:0036258	Multivesicular body assembly	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7
GO:0039702	Viral budding via host ESCRT complex	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP6, CHMP7
GO:0043112	Receptor metabolic process	CHMP5
GO:0043241	Protein complex disassembly	CHMP2A, CHMP2B, CHMP5, CHMP7
GO:0043900	Regulation of multi-organism process	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C
GO:0043901	Negative regulation of multi-organism process	CHMP3
GO:0043902	Positive regulation of multi-organism process	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C
GO:0043903	Regulation of symbiosis, encompassing mutualism through parasitism	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C
GO:0044770	Cell cycle phase transition	CHMP2A, CHMP4B, CHMP7
GO:0044772	Mitotic cell cycle phase transition	CHMP2A, CHMP4B, CHMP7
GO:0044801	Single-organism membrane fusion	CHMP2B, CHMP3
GO:0044803	Multi-organism membrane organization	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7
GO:0045022	Early endosome to late endosome transport	CHMP3
GO:0045047	Protein targeting to ER	CHMP4B
GO:0045324	Late endosome to vacuole transport	CHMP7
GO:0045786	Negative regulation of cell cycle	CHMP2A, CHMP4C
GO:0045921	Positive regulation of exocytosis	CHMP2A
GO:0046599	Regulation of centriole replication	CHMP2A
GO:0046600	Negative regulation of centriole replication	CHMP2A
GO:0046605	Regulation of centrosome cycle	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5
GO:0046606	Negative regulation of centrosome cycle	CHMP2A
GO:0046755	Viral budding	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7
GO:0048284	Organelle fusion	CHMP2B, CHMP3, CHMP4C
GO:0048524	Positive regulation of viral process	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C
GO:0048871	Multicellular organismal homeostasis	CHMP4B
GO:0050000	Chromosome localization	CHMP2A, CHMP2B, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7
GO:0048525	Negative regulation of viral process	CHMP3

Table 2 (continued)

Table 2 (continued)

Ontology ID	Description	Genes
GO:0050792	Regulation of viral process	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C
GO:0050890	Cognition	CHMP2B
GO:0051047	Positive regulation of secretion	CHMP2A
GO:0051225	Spindle assembly	CHMP2A, CHMP2B, CHMP4B, CHMP4C, CHMP5
GO:0051258	Protein polymerization	CHMP2A, CHMP3
GO:0051259	Protein oligomerization	CHMP2A, CHMP3, CHMP4B
GO:0051260	Protein homooligomerization	CHMP2A, CHMP4B
GO:0051291	Protein heterooligomerization	CHMP2A, CHMP3
GO:0051297	Centrosome organization	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5
GO:0051298	Centrosome duplication	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5
GO:0051302	Regulation of cell division	CHMP4C
GO:0051303	Establishment of chromosome localization	CHMP2A, CHMP2B, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7
GO:0051310	Metaphase plate congression	CHMP2A, CHMP2B, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7
GO:0051493	Regulation of cytoskeleton organization	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5
GO:0051494	Negative regulation of cytoskeleton organization	CHMP2A
GO:0060627	Regulation of vesicle-mediated transport	CHMP3
GO:0051640	Organelle localization	CHMP2A, CHMP2B, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7
GO:0051656	Establishment of organelle localization	CHMP2A, CHMP2B, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7
GO:0051782	Negative regulation of cell division	CHMP4C
GO:0051783	Regulation of nuclear division	CHMP2A, CHMP2B, CHMP4B, CHMP4C, CHMP5
GO:0060249	Anatomical structure homeostasis	CHMP2B, CHMP4B
GO:0060627	Regulation of vesicle-mediated transport	CHMP2A
GO:0061025	Membrane fusion	CHMP2B, CHMP3
GO:0061511	Centriole elongation	CHMP2A
GO:0061763	Multivesicular body-lysosome fusion	CHMP2B, CHMP3
GO:0070050	Neuron cellular homeostasis	CHMP2B
GO:0070507	Regulation of microtubule cytoskeleton organization	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5
GO:0070972	Protein localization to endoplasmic reticulum	CHMP4B
GO:0070997	Neuron death	CHMP4B
GO:0071985	Multivesicular body sorting pathway	CHMP3, CHMP5
GO:0072599	Establishment of protein localization to endoplasmic reticulum	CHMP4B

Table 2 (continued)

Table 2 (continued)

Ontology ID	Description	Genes
GO:0072657	Protein localization to membrane	CHMP4B
GO:0080171	Lytic vacuole organization	CHMP5
GO:0090148	Membrane fission	CHMP4B
GO:0090150	Establishment of protein localization to membrane	CHMP4B
GO:0090169	Regulation of spindle assembly	CHMP2A, CHMP2B, CHMP4B, CHMP4C, CHMP5
GO:0090174	Organelle membrane fusion	CHMP2B, CHMP3
GO:0090224	Regulation of spindle organization	CHMP2A, CHMP2B, CHMP4B, CHMP4C, CHMP5
GO:0090307	Mitotic spindle assembly	CHMP2A, CHMP2B, CHMP4B, CHMP4C, CHMP5
GO:0090611	Ubiquitin-independent protein catabolic process via the multivesicular body sorting pathway	CHMP4B, CHMP4C
GO:0097352	Autophagosome maturation	CHMP3
GO:0097576	Vacuole fusion	CHMP2B, CHMP3
GO:0098534	Centriole assembly	CHMP2A
GO:0098813	Nuclear chromosome segregation	CHMP2A, CHMP2B, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7
GO:0098927	Vesicle-mediated transport between endosomal compartments	CHMP3
GO:1901673	Regulation of mitotic spindle assembly	CHMP2A, CHMP2B, CHMP4C, CHMP5
GO:1901214	Regulation of neuron death	CHMP4B
GO:1902115	Regulation of organelle assembly	CHMP2A, CHMP2B, CHMP4B, CHMP4C, CHMP5
GO:1902116	Negative regulation of organelle assembly	CHMP2A, CHMP4B
GO:1902186	Regulation of viral release from host cell	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C
GO:1902187	Negative regulation of viral release from host cell	CHMP3
GO:1902188	Positive regulation of viral release from host cell	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C
GO:1902590	Multi-organism organelle organization	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7
GO:1902592	Multi-organism membrane budding	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7
GO:1903335	Regulation of vacuolar transport	CHMP3
GO:1903649	Regulation of cytoplasmic transport	CHMP3
GO:1902850	Microtubule cytoskeleton organization involved in mitosis	CHMP2A, CHMP2B, CHMP4B, CHMP4C, CHMP5
GO:1903532	Positive regulation of secretion by cell	CHMP2A
GO:1903541	Regulation of exosomal secretion	CHMP2A
GO:1903543	Positive regulation of exosomal secretion	CHMP2A
GO:1903722	Regulation of centriole elongation	CHMP2A
GO:1903723	Negative regulation of centriole elongation	CHMP2A

Table 2 (continued)

Table 2 (continued)

Ontology ID	Description	Genes
GO:1903900	Regulation of viral life cycle	CHMP2A, CHMP2B, CHMP3, CHMP4C
GO:1903901	Negative regulation of viral life cycle	CHMP3
GO:1903902	Positive regulation of viral life cycle	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C
GO:1904895	ESCRT complex assembly	CHMP6
GO:1904896	ESCRT complex disassembly	CHMP2A, CHMP5, CHMP7
GO:1904902	ESCRT III complex assembly	CHMP6
GO:1904903	ESCRT III complex disassembly	CHMP2A, CHMP5, CHMP7
GO:1905037	Autophagosome organization	CHMP4B
GO:1990182	Exosomal secretion	CHMP2A
GO:2000641	Regulation of early endosome to late endosome transport	CHMP3
GO:2000785	Regulation of autophagosome assembly	CHMP4B
MF		
GO:0002020	Protease binding	CHMP3
GO:0031210	Phosphatidylcholine binding	CHMP2A, CHMP3
GO:0045296	Cadherin binding	CHMP2B, CHMP4B, CHMP5
GO:0047485	Protein N-terminus binding	CHMP6
GO:0050839	Cell adhesion molecule binding	CHMP2B, CHMP4B, CHMP5
GO:0008565	Protein transporter activity	CHMP7
GO:0098631	Protein binding involved in cell adhesion	CHMP2B, CHMP4B, CHMP5
GO:0098632	Protein binding involved in cell-cell adhesion	CHMP2B, CHMP4B, CHMP5
GO:0098641	Cadherin binding involved in cell-cell adhesion	CHMP2B, CHMP4B, CHMP5
GO:0070405	Ammonium ion binding	CHMP2A, CHMP3
GO:1990381	Ubiquitin-specific protease binding	CHMP3
CC		
GO:000815	ESCRT III complex	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP6, CHMP7
GO:0005635	Nuclear envelope	CHMP2A, CHMP4B, CHMP7
GO:0005770	Late endosome	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP6
GO:0005913	Cell-cell adherens junction	CHMP5
GO:0010008	Endosome membrane	CHMP2A, CHMP2B, CHMP3, CHMP4C, CHMP5, CHMP6, CHMP7
GO:0030117	Membrane coat	CHMP2A
GO:0030496	Midbody	CHMP4C
GO:0031902	Late endosome membrane	CHMP2A, CHMP2B, CHMP3, CHMP4C, CHMP6
GO:0036452	ESCRT complex	CHMP2A, CHMP2B, CHMP3, CHMP4C, CHMP6, CHMP7

Table 2 (continued)

Table 2 (continued)

Ontology ID	Description	Genes
GO:0044440	Endosomal part	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5, CHMP7
GO:0048475	Coated membrane	CHMP2A, CHMP4B
GO:0090543	Flemming body	CHMP4C
GO:0098552	Side of membrane	CHMP4B
GO:0098562	Cytoplasmic side of membrane	CHMP4B
KEGG pathway		
Hsa04144	Endocytosis	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5
Reactome pathway		
R-HAS-162588	Budding and maturation of HIV virion	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7
R-HAS-2262752	Cellular responses to stress	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP6, CHMP7
R-HAS-421837	Clathrin derived vesicle budding	CHMP2A
R-HAS-1643685	Disease	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7
R-HAS-917729	Endosomal Sorting Complex Required For Transport (ESCRT)	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7
R-HAS-162906	HIV Infection	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7
R-HAS-162587	HIV Life Cycle	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7
R-HAS-5663205	Infectious disease	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7
R-HAS-162599	Late Phase of HIV Life Cycle	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7
R-HAS-432720	Lysosome Vesicle Biogenesis	CHMP2A
R-HAS-1632852	Macroautophagy	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP6, CHMP7
R-HAS-199991	Membrane Trafficking	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7
R-HAS-5653656	Vesicle-mediated transport	CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP4C, CHMP5, CHMP6, CHMP7
R-HAS-199992	Trans-Golgi Network Vesicle Budding	CHMP2A

BP, biological process; CC, cellular component; ESCRT, MF, molecular function; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes; ER, endoplasmic reticulum; HIV, human immunodeficiency virus.




Figure 3 Relationship between the abundance of TILs and gene expression. This was determined via conducting the Spearman correlation in the EC sample on the TCGA-UCEC database in the TISDB analysis. The stacked bar graph shows the infiltration of 28 immune cells in each sample. Each color represents a rho (A) or P value (B) in a type of immune cell. The X axis represents the association between the ESCRT pathway gene expression and immune subtypes across UCEC. The Y axis represents the TIL abundance Kruskal-Wallis Test ($-\log_{10} p$). (A) Rho in Lymphocyte; (B) P value in Lymphocyte; (C) the difference between the ESCRT genes: *CHMP2A*, *CHMP2B*, *CHMP3*, *CHMP4B*, *CHMP4C*, *CHMP5*, *CHMP5*, *CHMP7* and TILs on TCGA-UCEC tumor, normal and GTEx-Uterus dataset. The Y axis represents log (TPM+1) in GEPIA analysis. UCEC, uterine corpus endometrial carcinoma; TPM, transcripts per million; TILs, tumor-infiltrating immune cells; Act CD8, activated CD8 T cell; Tem CD8, central memory CD8 T cell; Tem CD8, effector memory CD8 T cell; Act CD4, Activated CD4 T cell; Tem CD4, central memory CD4 T cell; Tem CD4, Effector memory CD4 T cell; Tfh, T follicular helper cell; Tgd, gamma delta T cell; Th1, type 1 T helper cell; Th17, type 17 T helper cell; Th2, type 2 T helper cell; Treg, regulatory T cell; Act B, activated B cell; Imm B, immature B cell; Mem B, memory B cell; NK, natural killer cell; CD56bright, CD56bright natural killer cell; CD56dim, CD56dim natural killed cell; MDSC, myeloid derived suppressor cell; NKT, natural killer T cell; Act DC, activated dendritic cell; pDC, plasmacytoid dendritic cell; iDC, immature dendritic cell.

Table 3 Relationship between TILs (rho value) and ESCRT genes by multiple liner regression

Model	CHMP2A	CHMP2B	CHMP3	CHMP4B	CHMP4C	CHMP5	CHMP6	CHMP7
Parameter estimates	0.1175	-0.002861	0.01904	0.1020	-0.09654	0.05768	0.09136	0.01939
Standard error	0.04108	0.03143	0.02620	0.02584	0.02275	0.02394	0.03072	0.02259
95% CI	0.03321 to 0.2018	-0.06735 to 0.06163	-0.03473 to 0.07280	0.04903 to 0.1550	-0.1432 to -0.04985	0.008554 to 0.1068	0.02832 to 0.1544	-0.02697 to 0.06575
[t]	2.860	0.09102	0.7264	3.950	4.243	2.409	2.974	0.8583
P value	0.0081	0.9281	0.4738	0.0005	0.0002	0.0231	0.0061	0.3983

TILs, tumor-infiltrating immune cells; ESCRT, endosomal sorting complex required for transport; CI, confidence interval.

significantly lower, whereas *CHMP2A* and *CHMP4C* were significantly higher in EC samples than in normal tissues. Since histological grade and clinical stage greatly affected the prognosis prediction of EC (1), we explored it found that all of the ESCRT pathway genes were significantly differentially expressed between grades 2 and 3. Increased expression of *CHMP2A* and *CHMP7* and decreased expression of *CHMP4B* were related to endometrioid carcinoma samples compared with serous carcinoma samples. Furthermore, the results of the survival analysis revealed that upregulation of *CHMP2A* and *CHMP7* and downregulation of *CHMP4B* corresponded to a good prognosis in patients with EC. All three genes were significantly associated with all four molecular subtypes in TCGA. Therefore, we indicated that high levels of *CHMP2A* and *CHMP7* and low levels of *CHMP4B* were associated with good prognostic tumor type and early grade and were effective indicators of good prognosis in EC. *CHMP2A*, *CHMP2B*, *CHMP3*, *CHMP4B*, *CHMP4C*, and *CHMP5* were significantly correlated with HIPPO, WNT, mTOR, NRF2, RTK, P53/Rb, SWI-SNF, MYC/MYCIN pathway, and chromatin modifier status in EC tissues. As such, temsirolimus and everolimus, which are mTOR inhibitors, are effective in the treatment of recurrent chemotherapy (18,19). Moreover, *ESCRT-III* genes are effective markers for targeted therapy.

We found that most of the ESCRT pathway genes were frequently mutated in EC samples compared with the other cancer types obtained from the TCGA cohort. Additionally, missense mutations were the most common type of mutation. *CHMP7* was the first modifier of VEP impact mutation, which was deleterious and tolerated by the SIFT Impact Mutation. Mutations in *CHMP2A* and *CHMP7* had a good prognostic potential in EC. Dysfunction of ESCRT was associated with cancer, myopathy, and

neurodegeneration. Missense mutations in *CHMP4B* were associated with posterior subcapsular or polar cataracts (20-22). Other studies showed that *CHMP2B* mutations that were linked to defects in the process of dissociation from ESCRT disrupted endosome-to-lysosome trafficking, degradation, and recycling. Thus, this resulted in defective mitochondria, imbalanced iron homeostasis, reactive oxygen species, neuronal damage (23,24), endocytic and autophagic defects (25-27) in autosomal dominant presenile dementia (28), amyotrophic lateral sclerosis, cortical basal degeneration (CBD) or familial frontotemporal lobar degeneration (FTLD) and frontotemporal dementia (FTD) (29).

The results of functional analysis revealed that the endocytosis and ESCRT was the most significantly enriched KEGG and Reactome pathways associated with the ESCRT genes in ECs. All concerned ESCRT pathway genes were mainly involved in the BPs of membrane budding, multivesicular body organization, and assembly. The main related CC were the ESCRT and ESCRT III complex. The latter was involved in transmembrane protein delivery and in the promotion of nuclear envelope sealing and mitotic spindle disassembly during the late endosome anaphase (30). Protein sorting from the endosome to the vacuole/lysosome transportation and degradation in eukaryotic cells required the formation of MVBs, which, in turn, required the sequential functioning of ESCRT, -I, -II, and -III complexes in four steps: cargo recognition and sorting, which was initiated by the binding of ESCRT-0 to the Phosphatidylinositol 3-phosphate (PI3P) on endosomes; cargo sequestration, in which ESCRT-0 recruited ESCRT-I and interacted with ESCRT-II and -III; MVB vesicle formation, in which *ESCRT-III* proteins dissociated and assembled; and the ESCRT disassembly, in which the final step of the MVB pathway was formed (31-33). *CHMP5* served as an acceptor for the ESCRT-II complex on the endosomal membranes

in the *ESCRT-III* complex, thus participating in ESCRT and ESCRT III complex assembly in BP, while *CHMP2A*, *CHMP5*, and *CHMP7* participated in the BP of ESCRT and ESCRT III complex disassembly. In the late stages of cytokinesis, *CHMP3* was responsible for endosomal sorting/trafficking of the EGF receptor. *CHMP4C* was a key component of the cytokinesis checkpoint that delayed abscission and prevented both premature chromosome bridges of the cells and the accumulation of DNA damages (34,35). *CHMP2B*, *CHMP3*, and *CHMP5* were involved in the BP of the multivesicular body sorting pathways and the regulation of early to late endosome transport. All of the key genes were significantly and positively correlated with each other, revealing that the ESCRT pathway might also be involved in the mechanism of the MVB pathway in EC.

On the other hand, tumor-infiltrating immune cells (TICs) modulated cancer cell functions in the tumor microenvironment (36). This could be a basis for immunotherapy, in which the endogenous immune response against tumor cells would be stimulated. Furthermore, this could be associated with the prognosis of patients with EC. ECs stimulate immune checkpoints and activate negative feedback mechanisms in a locally immunosuppressed environment to evade the immune system (37). Memory CD4+ T cells, activated NK cells, and dendritic cells all decreased with an increase in EC grade and stage, which was related to the occurrence of EC. However, high levels of Tregs indicate a good prognosis (38). Our preliminary results show strong correlations between all ESCRT genes and infiltration levels of multiple immune cell types in EC samples. *CHMP2A* and *CHMP7* were positively correlated with the infiltration of CD4 and negatively correlated with B cells, while *CHMP4B* was associated with the infiltration of CD4, CD8, Treg, and NK cells. These three genes may potentially be immune-related indicators for the prognosis of EC and may become the basis for EC immunotherapies.

It has been found that EC cells represent the highest activated programmed death receptor-1 (PD1)/PD-L1 expression in endometrioid endometrial adenocarcinoma (EEC), serous endometrial adenocarcinoma (ESC), and clear cell subtypes for 40–80%, 10–68%, and 23–69%, respectively. On the other hand, inactivate tumor-infiltrating CD4 and CD8 T cells are found in the tumor microenvironment (39). Targeting the PD1 pathway may be a great strategy in enhancing the antitumor immune response for EC treatment. Anti-PD-L1 antibodies, such as pembrolizumab, nivolumab, and atezolizumab, have

been proven clinically effective in tumors with mismatch-repair deficiency in EC patients in clinical trials, with a 13–48% ORR, 19.0% PFS, and 68.8% OS rates (40–44). Pembrolizumab is an immune checkpoint blockade anti-PD1 antibody that has been used in patients with POLE-mutated (43) and MMR-deficient endometrial cancer (45). We observed that, except for *CHMP7*, all other ESCRT genes were significantly associated with the immune subtype. *CHMP2A*, *CHMP4B*, *CHMP5*, and *CHMP7* were significantly associated with the POLE-mutated molecular subtype in TCGA, which was identified in 10% of endometrioid subtypes. Therefore, elucidation of *CHMP2A*, *CHMP4B*, *CHMP7*, and immune cell interplay would assist in the prediction of immunotherapy responses and development of novel immunotherapy targets.

Conclusions

Our present study confirmed that RNA expression data on multiple datasets showed the relationship between *ESCRT-III* genes and EC. *ESCRT-III* genes may be used as clinical biomarkers for the prognostic prediction and immunotherapy strategies in patients with EC. Further research should be conducted to determine the mechanisms of ESCRT genes as biomarkers and therapeutic targets for the treatment of EC.

Acknowledgments

We thank Elsevier Author Services (<https://webshop.elsevier.com/language-editing-services/language-editing/>) for its linguistic assistance during the preparation of this manuscript.

Funding: This work was supported by National Natural Science Foundation of China (Nos. 81902628, 81900036), Translational Medicine Cross Research Fund of Shanghai Jiao Tong University School of Medicine (No. ZH2018QNB08), Clinical Research Project of Shanghai Health Commission (No. 202040455) and Shanghai Songjiang District Science and Technology Research (Medical and Health) Project (Nos. 20SJKJGG139, 20SJKJGG304).

Footnote

Reporting Checklist: The authors have completed the STREGA reporting checklist. Available at <https://tcr>.

amegroups.com/article/view/10.21037/tcr-22-660/rc

Peer Review File: Available at <https://tcr.amegroups.com/article/view/10.21037/tcr-22-660/prf>

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at <https://tcr.amegroups.com/article/view/10.21037/tcr-22-660/coif>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This study conformed to the provisions of the Declaration of Helsinki (as revised in 2013).

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. *CA Cancer J Clin* 2022;72:7-33.
2. Bokhman JV. Two pathogenetic types of endometrial carcinoma. *Gynecol Oncol* 1983;15:10-7.
3. Connor EV, Rose PG. Management Strategies for Recurrent Endometrial Cancer. *Expert Rev Anticancer Ther* 2018;18:873-85.
4. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. *Science* 2018;359:1350-5.
5. Gong YN, Guy C, Olauson H, et al. *ESCRT-III* Acts Downstream of MLKL to Regulate Necroptotic Cell Death and Its Consequences. *Cell* 2017;169:286-300.e16.
6. Rühl S, Shkarina K, Demarco B, et al. ESCRT-dependent membrane repair negatively regulates pyroptosis downstream of GSDMD activation. *Science* 2018;362:956-60.
7. Dai E, Meng L, Kang R, et al. *ESCRT-III*-dependent membrane repair blocks ferroptosis. *Biochem Biophys Res Commun* 2020;522:415-21.
8. McCullough J, Frost A, Sundquist WI. Structures, Functions, and Dynamics of *ESCRT-III/Vps4* Membrane Remodeling and Fission Complexes. *Annu Rev Cell Dev Biol* 2018;34:85-109.
9. Liu J, Kang R, Tang D. *ESCRT-III*-mediated membrane repair in cell death and tumor resistance. *Cancer Gene Ther* 2021;28:1-4.
10. Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. *Neoplasia* 2017;19:649-58.
11. Zhong X, Liu Y, Liu H, et al. Identification of Potential Prognostic Genes for Neuroblastoma. *Front Genet* 2018;9:589.
12. Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Res* 2017;45:W98-W102.
13. Chen F, Chandrashekar DS, Varambally S, et al. Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. *Nat Commun* 2019;10:5679.
14. Ru B, Wong CN, Tong Y, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. *Bioinformatics* 2019;35:4200-2.
15. Charoentong P, Finotello F, Angelova M, et al. Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. *Cell Rep* 2017;18:248-62.
16. Hänzelmann S, Castelo R, Guinney J. GSEA: gene set variation analysis for microarray and RNA-seq data. *BMC Bioinformatics* 2013;14:7.
17. Cancer Genome Atlas Research Network; Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. *Nature* 2013;497:67-73.
18. Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. *J Clin Oncol* 2011;29:3278-85.
19. Slomovitz BM, Lu KH, Johnston T, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. *Cancer* 2010;116:5415-9.
20. Zhang XH, Da Wang J, Jia HY, et al. Mutation profiles of congenital cataract genes in 21 northern Chinese families. *Mol Vis* 2018;24:471-7.
21. Shiels A, Bennett TM, Knopf HL, et al. *CHMP4B*, a novel gene for autosomal dominant cataracts linked to chromosome 20q. *Am J Hum Genet* 2007;81:596-606.
22. Wang X, Wang D, Wang Q, et al. Broadening the

- Mutation Spectrum in GJA8 and *CHMP4B*: Novel Missense Variants and the Associated Phenotypes in Six Chinese Han Congenital Cataracts Families. *Front Med (Lausanne)* 2021;8:713284.
23. Zhang Y, Schmid B, Nikolaisen NK, et al. Patient iPSC-Derived Neurons for Disease Modeling of Frontotemporal Dementia with Mutation in *CHMP2B*. *Stem Cell Reports* 2017;8:648-58.
 24. Han JH, Ryu HH, Jun MH, et al. The functional analysis of the *CHMP2B* missense mutation associated with neurodegenerative diseases in the endo-lysosomal pathway. *Biochem Biophys Res Commun* 2012;421:544-9.
 25. Filimonenko M, Stuffers S, Raiborg C, et al. Functional multivesicular bodies are required for autophagic clearance of protein aggregates associated with neurodegenerative disease. *J Cell Biol* 2007;179:485-500.
 26. Isaacs AM, Johannsen P, Holm I, et al. Frontotemporal dementia caused by *CHMP2B* mutations. *Curr Alzheimer Res* 2011;8:246-51.
 27. Lu Y, Zhang Z, Sun D, et al. Syntaxin 13, a genetic modifier of mutant *CHMP2B* in frontotemporal dementia, is required for autophagosome maturation. *Mol Cell* 2013;52:264-71.
 28. Skibinski G, Parkinson NJ, Brown JM, et al. Mutations in the endosomal ESCRTIII-complex subunit *CHMP2B* in frontotemporal dementia. *Nat Genet* 2005;37:806-8.
 29. Toft A, Roos P, Jääskeläinen O, et al. Serum Neurofilament Light in Patients with Frontotemporal Dementia Caused by *CHMP2B* Mutation. *Dement Geriatr Cogn Disord* 2020;49:533-8.
 30. Schöneberg J, Lee IH, Iwasa JH, et al. Reverse-topology membrane scission by the ESCRT proteins. *Nat Rev Mol Cell Biol* 2017;18:5-17.
 31. Mierzwa BE, Chiaruttini N, Redondo-Morata L, et al. Dynamic subunit turnover in *ESCRT-III* assemblies is regulated by Vps4 to mediate membrane remodelling during cytokinesis. *Nat Cell Biol* 2017;19:787-98.
 32. Schöneberg J, Pavlin MR, Yan S, et al. ATP-dependent force generation and membrane scission by *ESCRT-III* and Vps4. *Science* 2018;362:1423-8.
 33. Maity S, Caillat C, Miguët N, et al. VPS4 triggers constriction and cleavage of *ESCRT-III* helical filaments. *Sci Adv* 2019;5:eaau7198.
 34. Liu B, Guo S, Li GH, et al. *CHMP4C* regulates lung squamous carcinogenesis and progression through cell cycle pathway. *J Thorac Dis* 2021;13:4762-74.
 35. Neggers JE, Paoletta BR, Asfaw A, et al. Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. *Cell Rep* 2020;33:108493.
 36. Costa AC, Santos JMO, Gil da Costa RM, et al. Impact of immune cells on the hallmarks of cancer: A literature review. *Crit Rev Oncol Hematol* 2021;168:103541.
 37. Di Tucci C, Capone C, Galati G, et al. Immunotherapy in endometrial cancer: new scenarios on the horizon. *J Gynecol Oncol* 2019;30:e46.
 38. Chen B, Wang D, Li J, et al. Screening and Identification of Prognostic Tumor-Infiltrating Immune Cells and Genes of Endometrioid Endometrial Adenocarcinoma: Based on The Cancer Genome Atlas Database and Bioinformatics. *Front Oncol* 2020;10:554214.
 39. Herzog TJ, Arguello D, Reddy SK, et al. PD-1, PD-L1 expression in 1599 gynecological cancers: Implications for immunotherapy. *Gynecol Oncol*. 2015;137:204-5.
 40. Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *N Engl J Med* 2015;372:2509-20.
 41. Ott PA, Bang YJ, Berton-Rigaud D, et al. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. *J Clin Oncol* 2017;35:2535-41.
 42. Makker V, Rasco DW, Dutcus CE, et al. A phase Ib/II trial of lenvatinib (LEN) plus pembrolizumab (Pembro) in patients (Pts) with endometrial carcinoma. *J Clin Oncol* 2017;35:5598.
 43. Mehnert JM, Panda A, Zhong H, et al. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. *J Clin Invest* 2016;126:2334-40.
 44. Santin AD, Bellone S, Buza N, et al. Regression of Chemotherapy-Resistant Polymerase ϵ (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab. *Clin Cancer Res* 2016;22:5682-7.
 45. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science* 2017;357:409-13.

Cite this article as: Yang Y, Wang M. Genomic analysis of the endosomal sorting required for transport complex III pathway genes as therapeutic and prognostic biomarkers for endometrial carcinoma. *Transl Cancer Res* 2022;11(9):3108-3127. doi: 10.21037/tcr-22-660

Table S1 ESCRT-III Gene Location on TISDIB dataset

Symbol	Chromosomal Location	Location	Subcellular Location										
			Cytoplasm	cytosol	Membrane	Lipid-anchor	Endosome membrane	Late endosome membrane	Peripheral membrane protein	Cytoplasmic side	Midbody Nucleus envelope	Cytoplasm Nucleus envelope	
CHMP2A	19q13.43	chr19:58551566-58555124 (GRCh38)							Y	Y	Y		
CHMP2B	3p 12.1	chr3:87227271-87255548 (GRCh38)	Y	Y					Y	Y			
CHMP3	2p 11.2	chr2:86503430-86620493 (GRCh38)	Y	Y	Y	Y	Y	Y	Y				
CHMP4B	20q11.22	chr20:33811304-33854366 (GRCh38)	Y	Y					Y	Y		Y	
CHMP4C	8q21.13	chr8:81732434-81759515 (GRCh38)	Y	Y					Y	Y		Y	
CHMP5	9p13.3	chr9:33264879-33282069 (GRCh38)		Y				Y	Y				
CHMP6	17q25.3	chr17:80991598-81009517 (GRCh38)				Y		Y	Y				
CHMP7	8p21.2	chr8:23243637-23262000 (GRCh38)											Y

Table S2 ESCRT-III Gene Synonyms on TISDIB dataset

Symbol	Aliases, Synonyms
CHMP2A	Cytoplasmic side Note = Localizes to the midbody of dividing cells. Localized in two distinct rings on either side of the Fleming body. BC-2; CHMP2; VPS2; VPS2A; putative breast adenocarcinoma marker (32kD); VPS2 homolog A (S. cerevisiae); chromatin modifying protein 2A; BC2; VPS2 homolog A; putative breast adenocarcinoma marker BC-2; vacuolar protein sorting-associated protein 2-1; vps2-1; hVps2-1; Chromatin-modifying protein 2a
CHMP2B	Cytoplasm, cytosol Late endosome membrane Peripheral membrane protein DKFZP564O123; CHMP2.5; VPS2B; VPS2 homolog B (S. cerevisiae); chromatin modifying protein 2B; ALS17; VPS2-2; VPS2 homolog B; vacuolar protein-sorting-associated protein 2-2; hVps2-2; Vacuolar protein sorting-associated protein 2-2; Chromatin-modifying protein 2b
CHMP3	Late endosome membrane Note = Localizes to the midbody of dividing cells. NEDF; CGI-149; VPS24; vacuolar protein sorting 24 (yeast); vacuolar protein sorting 24 homolog (S. cerevisiae); 25.1 protein; CHMP family, member 3; chromatin-modifying protein 3; neuroendocrine differentiation factor; vacuolar protein sorting 24 homolog; vacuolar protein sorting-associated protein 24; hVps24
CHMP4B	Midbody Nucleus envelope Note = Recruited to the nuclear envelope by CHMP7 during late anaphase. Localizes transiently to the midbody arms immediately before abscission dJ553F4.4; Shax1; SNF7-2; VPS32B; C20orf178; chromosome 20 open reading frame 178; chromatin modifying protein 4B; CTPP3; CTRCT31; Vps32-2; SNF7 homolog associated with Alix 1; Snf7 homologue associated with Alix 1; chromatin-modifying protein 4b; hSnf7-2; hVps32-2; vacuolar protein sorting-associated protein 32-2; vacuolar protein-sorting-associated protein 32-2
CHMP4C	Midbody ring Note=Localizes to the midbody during late cytokinesis. During its recruitment, localizes initially to the midbody arms, before being directed to the central region, the midbody ring, also called Flemming body. Phosphorylation at Ser-210 by AURKB triggers localization to midbody ring MGC22825; Shax3; VPS32C; Snf7 homologue associated with Alix 3; chromatin modifying protein 4C; SNF7-3; SNF7 homolog associated with Alix 3; chromatin-modifying protein 4c; hSnf7-3; hVps32-3; vacuolar protein sorting-associated protein 32-3; vps32-3
CHMP5	Peripheral membrane protein Note = Localizes to the midbody of dividing cells. Localized in two distinct rings on either side of the Fleming body HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; PNAS-2; SNF7 domain containing 2; SNF7 domain-containing protein 2; apoptosis-related protein PNAS-2; chromatin-modifying protein 5; hVps60; vacuolar protein sorting-associated protein 60
CHMP6	Lipid-anchor Note = Localizes to endosomal membranes FLJ11749; VPS20; chromatin modifying protein 6; chromatin-modifying protein 6; hVps20; vacuolar protein sorting-associated protein 20
CHMP7	Cytoplasm Nucleus envelope Note = Diffused localization, with some punctate distribution, especially in the perinuclear area (PubMed:16856878). Localizes to the nucleus envelope during late anaphase MGC29816; CHMP family, member 7; chromatin-modifying protein 7

Table S3 Categories and Cases of ESCRT mutation types on TCGA-UCEC project

Mutation categories	Mutation types	CHMP2A	CHMP2B	CHMP3	CHMP4B	CHMP4C	CHMP5	CHMP6	CHMP7
somatic mutation	Missense	36	41	30	26	40	23	30	58
	Stop Gained	4	5	4	2	3	2	1	5
	Frameshift	2	1	1	3	1			5
	Stop Lost			1			1		
	Moderate	36	41	30	26	40	23	30	58
	High	6	6	6	5	4	3	1	6
SSM, CNV	SSM Affected Cases	21	26	15	22	14	19	9	36
	CNV Gains	26	11	8	22	14	21	53	3
	CNV Losses	23	23	9	11	5	5	7	32
VEP impact mutation	modifier	22	31	16	12	9	16	3	43
	moderate	10	10	7	5	7	8	4	13
	low	4	4	3	5	2	3	5	6
	high	1	1	4	2	1	1	1	3
SIFT impact mutation	tolerated	3	3	4	3	5	6	1	9
	deleterious	7	7	5	2	2	2	3	4
	deleterious_low_confidence								1
	tolerated_low_confidence								1
Polyphen impact mutation	benign	3	4	5	4	4	7	2	9
	probably_damaging	5	7	3	1	2	1	2	3
	unknown	2							2
	possibly_damaging	2	2	2		1		2	1
Consequence type mutation	non_coding_transcript_exon_variant	8	9	11			5		39
	3_prime_UTR_variant	3	15	4	12	9	10		34
	downstream_gene_variant	17	20	10			7	2	32
	missense_variant	10	10	7	5	7	8	4	13
	upstream_gene_variant	5	1				4		13
	intron_variant	3	2	4			2	2	12
	synonymous_variant		3	1	5	2	3	4	5
	start_lost			1					
	5_prime_UTR_variant	4	7					1	2
	frameshift_variant								2
	splice_acceptor_variant						1	1	1
	splice_region_variant	1	1					1	1
	stop_gained	1	1		1	1			
Type mutation	single base substitution	22	30	16	23	17	22	9	41
	small insertion		3			1			
	small deletion		2		1	1			2
Variant caller mutation	varscan2	20	27	12	20	13	19	9	36
	muse	20	25	14	20	15	21	8	34
	mutect	21							32
	mutect2		29	15	20	19	22	8	
	somaticsniper	18	23	10	16		17	8	30

SSM, simple somatic mutation; SNV, single nucleotide variation.

Table S5 Relations between abundance of Tumor-infiltrating lymphocytes (TILs) and gene expression by spearman correlations in EC

Symbol	CHMP2A		CHMP2B		CHMP3		CHMP4B		CHMP4C		CHMP5		CHMP6		CHMP7	
TISIDB																
	rho	P	rho	P	rho	P	rho	P	rho	P	rho	P	rho	P	rho	P
Act CD8	0.389	<2.2e-16	-0.086	0.0438	-0.045	0.293	0.206	1.35e-06	-0.144	0.000769	0.064	0.133	0.243	1.06e-08	0.099	0.0212
Tcm CD8	0.09	0.0351	-0.06	0.163	0.102	0.0169	0.236	2.58e-08	-0.071	0.0977	0.128	0.0027	0.135	0.00155	0.026	0.543
Tem CD8	0.168	8.14e-05	-0.097	0.0228	-0.057	0.184	0.103	0.0157	-0.17	6.81e-05	-0.023	0.596	0.15	0.000461	-0.045	0.293
Act CD4	-0.232	4.33e-08	0.0329	3.86e-15	0.125	0.00345	-0.03	0.486	0.136	0.00147	0.289	7.83e-12	-0.153	0.000351	0.15	0.000458
Tcm CD4	0.308	2.62e-13	0.064	0.136	0.087	0.0429	0.259	9.49e-10	-0.013	0.77	0.166	1e-04	0.17	6.64e-05	0.132	0.00193
Tem CD4	-0.274	8.49e-11	0.434	<2.2e-16	0.303	5.57e-13	-0.008	0.857	0.186	1.26e-05	0.363	<2.2e-16	-0.197	3.78e-06	0.181	2.22e-05
Tfh	0.158	0.000209	0.144	0.00074	-0.066	0.124	0.14	0.00104	-0.225	1.12e-07	0.025	0.554	0.119	0.00522	-0.074	0.0849
Tgd	0.264	4.23e-10	0.001	0.981	0.103	0.0161	0.219	2.4e-07	-0.017	0.69	0.082	0.0556	0.211	7.25e-07	0.218	3.03e-07
Th1	0.073	0.0864	-0.044	0.305	-0.018	0.675	0.028	0.515	-0.153	0.000341	0.048	0.262	0.085	0.0474	-0.102	0.0172
Th17	0.215	4.26e-07	-0.153	0.00033	-0.089	0.0377	0.003	0.95	-0.069	0.105	-0.142	0.000882	0.103	0.0161	-0.142	0.000861
Th2	-0.383	<2.2e-16	0.297	1.7e-12	0.223	1.45e-07	-0.194	5.48e-06	0.147	0.000586	0.142	0.000875	-0.242	1.2e-08	0.103	0.0161
Treg	-0.035	0.414	0.035	0.41	0.081	0.0588	0.089	0.0382	-0.101	0.018	0.143	0.000804	0.061	0.157	0.064	0.134
Act B	0.154	0.000301	-0.203	1.76e-06	-0.216	3.75e-07	0.025	0.563	-0.246	6.4e-09	-0.084	0.0501	0.111	0.00957	-0.129	0.00263
Imm B	0.018	0.676	-0.077	0.0736	-0.092	0.0317	-0.026	0.537	-0.207	1.08e-06	0.034	0.432	-0.029	0.5	-0.163	0.000132
Mem B	-0.332	2.18e-15	0.132	0.00204	0.133	0.00181	-0.083	0.0516	-0.027	0.528	-0.01	0.809	-0.134	0.0017	-0.098	0.0214
NK	0.076	0.0746	0.011	0.79	0.107	0.0121	0.119	0.00551	-0.124	0.00376	0.048	0.261	0.141	0.000967	0.051	0.231
CD56bright	0.325	8.43e-15	-0.028	0.515	0.084	0.0486	0.269	2.13e-10	-0.054	0.205	0.106	0.0135	0.216	3.6e-07	0.161	0.000161
CD56dim	0.434	<2.2e-16	-0.356	4.95e-18	-0.216	3.89e-07	0.372	<2.2e-16	-0.177	3.15e-05	-0.126	0.00325	0.355	8.26e-18	-0.09	0.0361
MDSC	0.281	2.67e-11	-0.17	7.04e-05	-0.083	0.0538	0.164	0.000119	-0.225	1.11e-07	-0.02	0.646	0.24	1.46e-08	0.029	0.497
NKT	-0.005	0.902	0.021	0.63	-0.049	0.257	0.046	0.279	-0.192	6.16e-06	0.071	0.0985	-0.012	0.778	-0.07	0.104
Act DC	0.233	3.93e-08	0.048	0.262	0.056	0.192	0.286	1.13e-11	-0.086	0.0448	0.179	2.74e-05	0.177	3.38e-05	0.038	0.375
pDC	0.239	1.72e-08	0.133	0.00188	0.08	0.0632	0.165	0.000105	-0.1	0.0199	0.093	0.029	0.102	0.0174	0.081	0.06
iDC	0.06	0.162	0.315	7e-14	0.357	4.14e-18	0.061	0.152	0.106	0.0133	0.275	7.85e-11	-0.127	0.00291	0.211	6.9e-07
Macrophage	0.212	6.41e-07	-0.123	0.00403	-0.076	0.0769	0.14	0.00109	-0.243	9.26e-09	-0.05	0.241	0.219	2.59e-07	-0.063	0.14
Eosinophil	0.103	0.0165	0.001	0.974	-0.099	0.0208	-0.099	0.0213	-0.2	2.49e-06	0.047	0.272	-0.007	0.868	-0.087	0.0425
Mast	0.164	0.00012	-0.115	0.00732	-0.074	0.0828	0.027	0.527	-0.178	3.11e-05	-0.127	0.00291	0.108	0.0113	0.018	0.617
Monocyte	0.486	<2.2e-16	-0.131	0.00217	-0.011	0.805	0.316	5.37e-14	-0.136	0.00148	0.003	0.951	0.465	<2.2e-16	0.184	1.6e-05
Neutrophil	0.101	0.0187	-0.106	0.013	-0.117	0.00628	0.024	0.581	-0.12	0.00489	-0.109	0.0106	0.048	0.263	-0.14	0.00101
GEPIA2021																
	F	p	F	p	F	p	F	p	F	p	F	p	F	p	F	p
UCEC tumor	577.17	<1e-15	451.02	<1e-15	680.18	<1e-15	533.94	<1e-15	590.94	<1e-15	688.49	<1e-15	393.59	<1e-15	786.80	<1e-15
UCEC normal	83.86	<1e-15	137.56	<1e-15	163.87	<1e-15	128.64	<1e-15	222.59	<1e-15	207.66	<1e-15	46.59	<1e-15	193.17	<1e-15
Uterus	2022.39	<1e-15	1686.46	<1e-15	2523.61	<1e-15	1657.34	<1e-15	1572.16	<1e-15	2213.29	<1e-15	1499.31	<1e-15	2643.63	<1e-15

Table S6 Survival analysis of ESCRT genes in EC patients

Dataset	Symbol	CHMP2A	CHMP2B	CHMP3	CHMP4B	CHMP4C	CHMP5	CHMP6	CHMP7
TCGA	p	0.2	0.1		0.037	0.86	0.69	0.13	0.19
TISIDB	Log-rank p	0.0203	0.274	0.183	0.118	0.101	0.426	0.28	0.984
GEPIA									
OS	Log-rank p	0.14	0.91	0.85	0.45	0.22	0.68	0.97	0.14
	HR (high)	0.6	0.91	1.1	1.3	0.64	0.86	0.99	0.59
DFS	Log-rank p	0.016	0.12	0.97	0.89	0.16	0.17	0.19	0.027
	HR (high)	0.44	0.6	0.99	1	0.63	0.63	0.64	0.47




Figure S1 Endosomal sorting required for transport complex III (ESCRT-III) pathway. Cited from: TISIDB (<http://cis.hku.hk/TISIDB/index.php>). ESCRT, endosomal sorting complex required for transport, CHMP, charged multivesicular body protein.




Figure S2 A comparison of the expression levels of the endosomal sorting complex required for transport (ESCRT) pathway genes between EC and normal endometrial tissue samples. The gene expression profile across tumor samples and paired normal tissues are displayed by bar plot. The height of bar represents the median expression of EC tumor type or normal tissue. The X axis represents the association between ESCRT pathway gene expression in EC and normal endometrial tissue, while the Y axis represents the TPM (A), in UALCAN analysis on TCGA-UCEC database, and (B), in GEPIA analysis on TCGA-UCEC and GTEx- Uterus database. (C) Z-values represent the standard deviations from the median of Z-values across EC and normal group samples. *, $P < 0.05$ compared with normal endometrial tissues with boxplots. TPM: Transcripts Per Million; ESCRT: endosomal sorting complex required for transport; CHMP: charged multivesicular body protein; TCGA: dataset of the Cancer Genome Atlas database; UCEC: uterine corpus endometrial carcinoma.




Figure S3 Association between the ESCRT pathway gene expression and the EC immune and molecular subtype. The Y axis represents the log2CPM of expression, which has been determined by the Kruskal-Wallis test $-\log_{10}(p\text{-value})$. (A) Immune subtype: C1 (wound healing) (n=247); C2 (IFN-gamma dominant) (n=212); C3 (inflammatory) (n=52); C4 (lymphocyte depleted) (n=16); C5 (immunologically quiet) (n=0); C6 (TGF- β dominant) (n=1). (B) Molecular subtype: Molecular subtype: POLE (DNA polymerase epsilon) (n=79), low copy number (CN-LOW) (n=144), high copy number (CN-HIGH) (n=160), and microsatellite instability (MSI) (n=124).




Figure S4 Correlations among the ESCRT pathway gene expression with Transcripts Per Million (TPM) by Pearson correlation analysis.





Figure S5 The ESCRT pathway gene mutations across different cancer types compared with those in EC. This was based on the TCGA database. Different genes are represented in the waterfall plot column. ACC, Adrenocortical carcinoma, BRCA, Breast invasive carcinoma, BLCA, Bladder urothelial carcinoma, CESC, Cervical squamous cell carcinoma, COAD, Colon adenocarcinoma, CPTAC-2, CPTAC-Breast, Colon, Ovary, CPTAC-3, CPTAC-Brain, Head and Neck, Kidney, Lung, Pancreas, Uterus, CMI-MBC, Count Me In (CMI): The Metastatic Breast Cancer (MBC) Project, DLBC, Lymphoid Neoplasm Diffuse Large B-cell Lymphoma, ESCA, Esophageal carcinoma, GBM, Glioblastoma multiforme, HNCMI-CMDC, NCI Cancer Model Development for the Human Cancer Model Initiative, HNSC, Head and Neck squamous cell carcinoma, KIRC, Kidney renal clear cell carcinoma, KIRP, Kidney renal papillary cell carcinoma, LAML, Acute Myeloid Leukemia, LUAD, Lung adenocarcinoma, LUSC, Lung squamous cell carcinoma, LIHC, Liver Hepatocellular Carcinoma, LGG, Brain Lower Grade Glioma, MMRF-COMMPASS, Multiple Myeloma CoMMpass Study, OV, Ovarian serous cystadenocarcinoma, PAAD, Pancreatic adenocarcinoma, PRAD, Prostate adenocarcinoma, READ, Rectum adenocarcinoma, SARC, Sarcoma, STAD, Stomach adenocarcinoma, SKCM, Skin cutaneous melanoma, TARGET-NBL, Neuroblastoma, TGCT, Testicular Germ Cell Tumors, UCS, Uterine carcinosarcoma, UCEC, Uterine corpus endometrial carcinoma.






Figure S7 Survival analysis on ESCRT-III mutation genes: CHMP2A, CHMP2B, CHMP3, CHMP4B, CHMP5, CHMP6, CHMP7.